These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 14602723)

  • 1. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD; Kao MC; Lin JK
    J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells.
    Way TD; Kao MC; Lin JK
    FEBS Lett; 2005 Jan; 579(1):145-52. PubMed ID: 15620704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Münster PN; Marchion DC; Basso AD; Rosen N
    Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
    Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway.
    Guo G; Zhang W; Dang M; Yan M; Chen Z
    J Biochem Mol Toxicol; 2019 Apr; 33(4):e22268. PubMed ID: 30431692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
    Basso AD; Solit DB; Munster PN; Rosen N
    Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
    Serra V; Scaltriti M; Prudkin L; Eichhorn PJ; Ibrahim YH; Chandarlapaty S; Markman B; Rodriguez O; Guzman M; Rodriguez S; Gili M; Russillo M; Parra JL; Singh S; Arribas J; Rosen N; Baselga J
    Oncogene; 2011 Jun; 30(22):2547-57. PubMed ID: 21278786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
    Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
    Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling.
    Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
    Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
    Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.
    Jang JY; Jeon YK; Kim CW
    BMC Cancer; 2010 Jul; 10():391. PubMed ID: 20650008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.